Research Article

Analysis of Transcription Factor-Related Regulatory Networks Based on Bioinformatics Analysis and Validation in Hepatocellular Carcinoma

Shui Liu 1,2, Xiaoxiao Yao 1,2, Dan Zhang 1,2, Jiyao Sheng 1,2, Xin Wen 3, Qingyu Wang 4, Gaoyang Chen 4, Zhaoyan Li 4, Zhenwu Du 4,5 and Xuewen Zhang 1,2

1Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun 130041, China
2Jilin Engineering Laboratory for Translational Medicine of Hepatobiliary and Pancreatic Diseases, The Second Hospital of Jilin University, Changchun 130041, China
3The Second Hospital of Jilin University, Changchun 130041, China
4Department of Orthopedics, The Second Hospital of Jilin University, Changchun 130041, China
5Research Center of Second Clinical College, Jilin University, Changchun 130041, China

Correspondence should be addressed to Zhenwu Du; doom99I06@163.com and Xuewen Zhang; zhangxw@jlu.edu.cn

Received 2 April 2018; Revised 3 July 2018; Accepted 25 July 2018; Published 29 August 2018

Academic Editor: Ji-Fu Wei

Copyright © 2018 Shui Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular carcinoma (HCC) accounts for a significant proportion of liver cancer, which has become the second most common cause of cancer-related mortality worldwide. To investigate the potential mechanisms of invasion and progression of HCC, bioinformatics analysis and validation by qRT-PCR were performed. We found 237 differentially expressed genes (DEGs) including EGR1, FOS, and FOSB, which were three cancer-related transcription factors. Subsequently, we constructed TF-gene network and miRNA-TF-mRNA network based on data obtained from mRNA and miRNA expression profiles for analysis of HCC. We found that 42 key genes from the TF-gene network including EGR1, FOS, and FOSB were most enriched in the p53 signaling pathway. The qRT-PCR data confirmed that mRNA levels of EGR1, FOS, and FOSB all were decreased in HCC tissues. In addition, we confirmed that the mRNA levels of CCNB1, CCNB2, and CHEK1, three key markers of the p53 signaling pathway, were all increased in HCC tissues by bioinformatics analysis and qRT-PCR validation. Therefore, we speculated that miR-181a-5p, which was upregulated in HCC tissues, could regulate FOS and EGR1 to promote the invasion and progression of HCC by p53 signaling pathway. Overall, the study provides support for the possible mechanisms of progression in HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the common digestive system malignancies with high mortality, which has become the second most common cause of cancer-related mortality worldwide [1, 2]. There are more than 466,100 estimated new cases and 422,100 estimated death cases every year in China [3]. Although there is extensive research about the therapies for HCC, the specific mechanisms of HCC occurrence and development were not clear. It is significant to investigate the underlying mechanisms of HCC invasion and progression to develop effective diagnostic and therapeutic strategy.

Over the last decades, bioinformatics and microarray technology have been widely used to screen the molecular mechanisms of HCC, which provide powerful research support for the diagnosis and treatment of HCC [4–6]. By bioinformatics analysis and microarray technology, functions of some differentially expressed genes (DEGs) in HCC have been explored, which paved the way for exploring complicated process in the occurrence and development of HCC [5,7–9]. As an important part of participating in life activities,
transcription factors (TFs) have been reported to play an important role in the development of HCC by numerous studies [10, 11]. A work by S. Hua et al. found that ETS1, a cancer-related TF, could through interaction with miR-139-5p inhibit cell proliferation, migration, and invasion in HCC [12]. Another research reported that NFκB/EGFR1 signaling pathway induced miR-3928v to promote the progression of HCC [13]. Even so, more research is still needed to explore the specific role of different TFs in the progression of HCC.

During the present study, we analyzed 4 mRNA microarray datasets and 1 mRNA microarray dataset from Gene Expression Omnibus (GEO) to obtain DEGs and differentially expressed miRNAs (DEMs) between HCC tissues and adjacent noncancerous tissues by GEO2R. Subsequently, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed to reveal the interaction relationship between DEGs and DEMs and to explore the underlying molecular mechanisms in the carcinogenesis and progression of HCC [14–17]. In addition, we screened differentially expressed TFs in HCC, constructed miRNA-TF-mRNA networks, and proposed a potential miRNA-TF-signaling pathway axis, which identified a systematic exposition of the relevant transcriptional regulation modes associated with invasion and progression of HCC. This study could provide insightful information and the valuable clue for biomarker discovery and novel treatment strategy in HCC.

2. Materials and Methods

2.1. Microarray Data Information and DEGs Identification. NCBI-GEO is a free database of microarray/gene profile and next-generation sequencing, from which HCC and adjacent nontumor tissue gene expression profile of GSE84402, GSE33006, GSE84005, GSE12941, and GSE64632 were obtained [4, 18, 19, 21]. The DEGs and DEMs between HCC tissues and adjacent nontumor tissues were screened using GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/), which was an interactive web tool for identifying DEGs across experimental conditions among two or more datasets in a GEO series. Identification of commonly differentially expressed mRNAs from the four cohort profile data sets (GSE84402, GSE33006, GSE84005, and GSE12941) was performed by FunRich software (available online: http://www.funrich.org/). |logFC| (fold change) >1 and P value <0.05 were considered statistically significant. The pipeline of the whole process of this study was shown in Figure 1.

2.2. Construction of Transcription Factor Networks. Transcriptional regulatory element database (TRED) (https://ch.uta.dallas.edu/cgibin/TRED/tred.cgi?process=home) is a database of transcriptional regulatory elements, which provides 36 cancer-related TFs and corresponding regulatory networks [22]. Transcriptional Regulatory Relationships Unraveled by Sentenced-based Text mining version 2.0 database (TRRUST) (available online: http://www.gramedia.org/trrust/) is a database based on the literature to reflect the relationship between transcriptional regulation [23]. And the prediction of miRNA-target genes was performed by miRTarBase (http://mirtar-base.mbc.nctu.edu.tw/php/index.php) [24]. According to the regulatory interaction, TF-target network and miRNA-TF-mRNA network were constructed based on gene expression profile, TRRUST version 2, TRED, and miRTarBase by Cytoscape 3.6.0 software.

2.3. Functional and Pathway Enrichment Analysis. Omicsbean is an online biological information database that integrates biological data and analysis tools and provides a comprehensive set of functional annotation information of genes and proteins for users to extract biological information. To analyze the function of DEGs, GO and KEGG pathway enrichment analysis were performed using Omicsbean online database (http://www.omicsbean.com:88). P value<0.05 was considered statistically significant.

2.4. Validation in TCGA Dataset and Modular Analysis of the Key Genes. Validation of the key genes in the TCGA Data-set was performed by UALCAN (http://ualcan.path.uab.edu/index.html) [25]. We performed Kaplan-Meier plots and boxplots to verify the differential expression of the key genes between primary tumor and normal liver and effect of key genes expression level on LIHC patients' survival. Correlation analysis was performed by Linkedomics (http://www.linkedomics.org) [26].

2.5. Validation of the Key Genes by Quantitative Real-Time RTPCR (qRT-PCR). A total of 20 HCC patients were recruited for tumor and adjacent nontumor tissues collection from the China-Japan Union Hospital of Jilin University, Changchun, China. This study was approved by the Ethics Committee of the Second Clinical Medical College, Jilin University, and each patient consented in a written informed consent form. The data were analyzed anonymously. All tissues were taken from the surgery room and snap-frozen and stored in liquid nitrogen within 10 min after the resection. The clinicopathological characteristics of 20 HCC patients were shown in Table S1.

Tissue RNA was isolated using Trizol (Invitrogen, CA, USA) and further purified using the MiniBEST Universal RNA Extraction Kit (TaKaRa, China) according to the manufacturer’s instructions. RNA concentration was then measured using the NanoDrop 2000 spectrophotometer (Thermo Scientific, MA, USA) with A260/A280 ratio in the range 1.8–2.0 and RNA concentration ranged from 100 ng/μl to 1 μg/μl. For qRT-PCR analysis, less than 5 μg total RNA including microRNA was reverse transcribed to cDNA with 1st strand cDNA Synthesis Kit (TaKaRa, China) and miRNA First Strand cDNA Synthesis (Sangon, China); the expression of mRNA and microRNA was examined by qRT-PCR with TransStart ® Top Green qPCR SuperMix (TransGen Biotech, China), microRNAs qPCR Kit (Sangon, China), and Applied Biosystems 7500 Fast Real-Time PCR System. The relative expression of mRNA and microRNA was normalized to GAPDH/U6 expression by comparative Ct method (2^-ΔΔCt, ΔCt =Ct_target-Ct_GAPDH/U6, and ΔΔCt=ΔCt_tumor-ΔCt_nontumor). All primers were designed with Primer 7.0.
Figure 1: Process of TF-related regulatory network construction and key genes identification in HCC.

Figure 2: Identification of 237 common DEGs from the four cohort profile data sets. (a) 57 commonly upregulated DEGs. (b) 180 commonly downregulated DEGs. Different color areas represented different datasets. The cross areas meant the commonly changed DEGs. DEGs were identified with classical t-test; statistically significant DEGs were defined with p < 0.05 and |logFC| > 1 as the cut-off criterion.

3. Results

3.1. Identification and Enrichment Analysis of DEGs in HCC. HCC and adjacent non-tumor tissue gene expression profile of GSE84402, GSE33006, GSE84005, and GSE12941 were obtained from NCBI-GEO. We used p<0.05 and |logFC| >1 as cut-off criterion. After integrated bioinformatical analysis, a total of 237 differentially expressed genes were identified from the four profile datasets, including 57 upregulated genes and 180 downregulated genes (Tables 1–3, Figure 2).

The enrichment analysis of DEGs was performed. As shown in Table 4 and Figure 3, in the biological process group, the DEGs were mainly enriched in response to chemical. In the cellular component group, the DEGs were most enriched in the extracellular region. In the molecular function group, the DEGs were most enriched in protein binding. And the most enriched KEGG pathway was complement and coagulation cascades.

3.2. Identification and Functional Analysis of Key Differentially Expressed Genes, Construction of TF-Related Networks in HCC. We intersected 237 common DEGs and curated 36 cancer-related TF families to get three differentially expressed TFs (EGRI, FOS, and FOSB) in HCC (Table 5). We searched Software; primer sequences for amplification were listed in Table 8.

2.6. Statistical Analysis. Data from qRT-PCR were analyzed with GraphPad Prism version 7.0, and differences between the two groups were statistically evaluated by two-tailed Student’s t-test with p value <0.05 considered as significant. The Pearson correlation coefficient was used to examine the relationship between key genes.
the target genes and regulators of the three TFs through TRRUST version 2 database. Based on the results, we found that STAT6, a cancer-related TF, regulated FOS and FOSB, while FOS and EGR1 were coregulated by 2 cancer-related TFs, including BRCA1 and SPI, respectively. Similarly, TP53 and NFKB1 were coregulated by FOS and EGR1, respectively. Since FOS and EGR1 are linked to each other by 4 cancer-related TFs including BRCA1, SPI, TP53, and NFKB1, we also

Figure 3: Enrichment analysis of DEGs.

Table 1: The information of expression profiles.

| Series     | Platform | Tissues | Adjacent tissues | Tumor tissues | Reference |
|------------|----------|---------|------------------|---------------|-----------|
| GSE84402   | GPL570   | mRNA    | Liver            | 14            | 14        | [4]       |
| GSE33006   | GPL570   | mRNA    | Liver            | 3             | 3         | [18]      |
| GSE84005   | GPL5175  | mRNA    | Liver            | 38            | 38        | [19]      |
| GSE12941   | GPL5175  | mRNA    | Liver            | 10            | 10        |           |
| GSE64632   | GPL18116 | miRNA   | Liver            | 3             | 3         | [20]      |
included these four TFs in the subsequent data of network construction. We screened the 4 TFs in the TRRUST version 2 database query to get each TF target genes and the DEGs from four profile datasets in GEO and TF-target genes for intersection analysis to obtain 42 differentially expressed target genes of the TFs (key genes) (Table 6), which laid the foundation for our next step to construct the gene signaling regulatory network in HCC.

Based on the above TRRUST version 2 database, we constructed the TF-target transcription regulatory network with the 42 key genes in HCC by Cytoscape 3.6.0 software (Figure 4). The TF-target network complex contained 42 key genes and 7 TFs. We performed enrichment analysis for the 42 key genes; the results were followed in Figure 6.

Subsequently, the HCC and adjacent tissue gene expression profile of GSE64632 were analyzed by GEO2R. We use p<0.05 and |logFC| >1 as cut-off criterion to obtain 703 DEMs, including 452 upregulated DEMs and 251 downregulated DEMs. The interactions between TFs and microRNAs were predicted by miRTarBase. And we performed intersection analysis between the miRNA-targeting genes and DEMs in the microRNA assay data from GEO. Based on the above TRRUST version 2 database and miRTarBase, we constructed miRNA-TF-mRNA regulatory network by Cytoscape software (Figure 5). The results showed that some genes were coregulated by the same miRNA or a few miRNAs, which suggested that miRNAs could play an important role in the progression of HCC. Using these coregulatory genes combined with regulatory networks, we constructed the miRNA-TF-mRNA regulatory network, which was shown in Figure 5.

In addition, the Prediction resultsofdifferentially expressed miRNA targets revealed that EGR1 and FOS are coregulated by 2 microRNAs including hsa-miR-181a-5p and hsa-miR-192-5p, which were upregulated in HCC based on microRNA assay data. In the targeting relationship between miR-181a-5p and EGR1, FOS has been experimentally validated, especially.

3.3. Functional and Pathway Analysis of the Key Genes. In the current study, we performed enrichment analysis for the 42 key genes which were differentially expressed in HCC tissues. And the results were shown in Figure 6 and Table 7. And the most enriched KEGG pathway of key genes was p53 pathway.
Table 4: Enrichment analysis of DEGs.

(a) Top 10 enriched biological processes of DEGs

| GO_Name                                   | GO_ID       | P value     | Count |
|-------------------------------------------|-------------|-------------|-------|
| response to chemical                      | GO:0042221  | 8.60E-31    | 103   |
| cellular response to chemical stimulus    | GO:0070887  | 9.67E-27    | 80    |
| response to stimulus                      | GO:0050896  | 2.83E-25    | 158   |
| single-organism metabolic process         | GO:0044710  | 1.07E-24    | 129   |
| response to organic substance             | GO:0010033  | 1.49E-22    | 75    |
| small molecule metabolic process          | GO:0044281  | 2.85E-22    | 76    |
| single-multicellular organism process     | GO:0044707  | 6.06E-20    | 109   |
| negative regulation of biological process | GO:0048519  | 6.44E-20    | 91    |
| negative regulation of cellular process   | GO:0048523  | 8.35E-20    | 86    |
| regulation of response to stimulus        | GO:0048583  | 9.64E-20    | 82    |

(b) Top 10 enriched cell components of DEGs

| GO_Name                                   | GO_ID       | P value     | Count |
|-------------------------------------------|-------------|-------------|-------|
| extracellular region                      | GO:0005576  | 1.17E-37    | 110   |
| extracellular region part                 | GO:0044421  | 3.22E-35    | 96    |
| membrane-bounded vesicle                  | GO:0031988  | 3.92E-29    | 83    |
| extracellular space                       | GO:0005615  | 5.47E-29    | 60    |
| vesicle                                   | GO:0031982  | 5.72E-29    | 89    |
| extracellular vesicle                     | GO:1903561  | 7.65E-27    | 67    |
| extracellular organelle                   | GO:0043230  | 7.96E-27    | 67    |
| extracellular membrane-bounded organelle  | GO:0065010  | 2.19E-26    | 66    |
| extracellular exosome                     | GO:0070062  | 3.55E-26    | 66    |
| cytoplasmic part                          | GO:0044444  | 6.80E-14    | 136   |

(c) Top 10 enriched molecular functions of DEGs

| GO_Name                                   | GO_ID       | P value     | Count |
|-------------------------------------------|-------------|-------------|-------|
| protein binding                           | GO:0005515  | 4.15E-21    | 146   |
| identical protein binding                 | GO:0042802  | 2.61E-09    | 30    |
| protein homodimerization activity         | GO:0042803  | 3.74E-09    | 22    |
| oxygen binding                            | GO:0019825  | 1.97E-08    | 8     |
| growth factor binding                     | GO:0019838  | 4.52E-08    | 10    |
| extracellular matrix binding              | GO:0050840  | 6.88E-08    | 7     |
| oxidoreductase activity                   | GO:0016491  | 7.54E-08    | 32    |
| binding                                   | GO:0005488  | 1.17E-07    | 186   |
| protein dimerization activity             | GO:0046983  | 1.97E-07    | 27    |
| oxidoreductase activity, acting on CH or CH2 groups | GO:0016725 | 2.42E-07 | 4     |

(d) Top 10 enriched KEGG pathways of DEGs

| Pathway Name                               | Pathway ID  | P value     | Count |
|--------------------------------------------|-------------|-------------|-------|
| Complement and coagulation cascades        | hsa04610    | 1.79E-06    | 10    |
| Metabolic pathways                         | hsa01100    | 1.78E-05    | 43    |
| p53 signaling pathway                      | hsa04115    | 3.88E-05    | 8     |
| Prion diseases                             | hsa05020    | 3.97E-05    | 6     |
| Histidine metabolism                       | hsa00340    | 6.78E-05    | 5     |
| Retinol metabolism                         | hsa00830    | 1.93E-04    | 7     |
| Steroid hormone biosynthesis               | hsa00140    | 6.97E-04    | 6     |
| Tryptophan metabolism                      | hsa00380    | 8.26E-04    | 5     |
| Cell cycle                                 | hsa04110    | 2.17E-03    | 8     |
| Caffeine metabolism                        | hsa00232    | 3.35E-03    | 2     |
Table 5: Curated 36 cancer-related TF families.

| Family | Full Name | Members (Official Gene Symbols) |
|--------|-----------|---------------------------------|
| AP1    | Activator Protein 1 | FOS, FOSB, JUN, JUNB, JUND |
| AP2    | Activator Protein 2 | TFAP2A, TFAP2B, TFAP2C, TFAP2D, TFAP2E |
| AR     | Androgen Receptor | AR |
| ATF    | Activating Transcription Factor | ATF1 – 7 |
| BCL    | B-cell CLL/lymphoma | BCL3, BCL6 |
| BRCA   | breast cancer susceptibility protein | BRCA1 – 3 |
| CEBP   | CCAAT/enhancer binding protein | CEBPA, CEBPB, CEBPD, CEBPE, CEBPG |
| CREB   | cAMP responsive element binding protein | CREB1 - 5, CREM |
| E2F    | E2F transcription factor | E2F1 – 7 |
| EGR    | early growth response protein | EGR1 – 4 |
| ELK    | member of ETS oncogene family | ELK1, ELK3, ELK4 |
| ER     | Estrogen Receptor | ESRI, ESRII |
| ERG    | ets-related gene | ERG |
| ETS    | ETS-domain transcription factor | ETS1, ETS2, ETV4, SPI |
| FLI1   | friend leukemia integration site1 | FLI1 |
| GLI    | glioma-associated oncogene homolog | GLI1 – 4 |
| HIF    | Hypoxia-inducible factor | HIF1A, ARNT, EPAS1, HIF3A |
| HLF    | hepatic leukemia factor | HLF |
| HOX    | homeobox gene | HOXA, HOXB, HOXD series, CHX10, MSX1, MSX2, TLX1, PBX2 |
| LEF    | lymphoid enhancing factor | LEF1 |
| MYB    | myeloblastosis oncogene | MYB, MYB1, MYB2 |
| MYC    | myelocytomatosis viral oncogene homolog | MYC |
| NFI    | nuclear factor I, CCAAT-binding transcription factor | NFIA, NFB, NFIC, NFIX |
| NFKB   | Nuclear factor kappa B, reticulonendotheliosis oncogene | NFKB1, NFKB2, RELA, RELB, REL |
| OCT    | Octamer binding proteins | POU2F1 - 3, POU3F1 - 2, POU5F1 |
| p53    | P53 family | TP53, TP73L, TP73 |
| PAX    | paired box gene | PAX1 – 9 |
| PPAR   | Peroxisome proliferator-activated receptor | PPARA, PPARD, PPARG |
| PR     | Progesterone Receptor | PGR |
| RAR    | retinoic acid receptor | RARA, RARB, RARG |
| SMAD   | Mothers Against Decapentaplegic homolog | SMAD1 - 9 |
| SP     | sequence-specific transcription factor | SPI – 8 |
| STAT   | signal transducer and activator of transcription | STAT1 - 6 |
| TAL1   | T-cell acute lymphocytic leukemia-1 protein | TAL1 |
| USF    | upstream stimulatory factor | USF1, USF2 |
| WT1    | Wilms tumor 1 (zinc finger protein) | WT1 |

We queried all the samples from TCGA liver hepatocellular carcinoma (LIHC) with RNA-seq v2 data in our study. The boxplots showed that the expression level of EGR1, FOS, and FOSB was significantly lower in primary tumor than that in the normal liver for LIHC patients from TCGA (p<0.001) (Figure 7(a)). The overall survival analysis of the three TFs was performed using the Kaplan-Meier curve. We found that the overexpression of FOSB in HCC was associated with reduced survival in cases with three TFs high expression, compared with the remaining cases with low/medium expression (Figure 7(b)). Through correlation analysis, we found that there was a strong positive correlation...
between the expression level of EGR1 and FOS mRNA. And there existed strong positive correlation toward coexpression of FOS and FOSB among target samples. The correlation between the expression level of EGR1 and FOSB mRNA was moderate (Figure 7(c)).

Moreover, CCNB1, CCNB2, and CHEK1, which were three of key genes in the TF-target network, were involved in the p53 pathway. The boxplots showed that the expression levels of CCNB1, CCNB2, and CHEK1 were significantly higher in primary tumor than those in the normal liver for
LIHC patients from TCGA (p < 0.001). The overall survival rates of patients with high expression of CCNB1, CCNB2, and CHEK1 were all significantly lower than those of patients with low/medium expression. The correlation analysis results showed that there existed strong positive correlation among CCNB1, CCNB2, and CHEK1 mRNA expression (Figure 7(c)).

3.4. qRT-PCR. We performed qRT-PCR to examine the expression of three differentially expressed TFs including EGR1, FOS, and FOSB mRNA in HCC. The relative expressions of EGR1, FOS, and FOSB mRNA were 0.493±0.558-, 0.494±0.476-, and 0.500±0.551-fold downregulated in 20 tumor tissues versus adjacent nontumor tissues, respectively (Figure 8). Similarly, we performed qRT-PCR to explore the relationship among miR-181a-5p, TFs, and the key markers of p53 signaling pathway including CCNB1, CCNB2, and CHEK1. The relative expressions of CCNB1, CCNB2, and CHEK1 mRNA were 3.938±3.887-, 3.225±3.388-, and 3.186±3.508-fold upregulated in 20 tumor tissues versus adjacent nontumor tissues, respectively (Figure 8). And the relative expression of hsa-miR-181a-5p was 1.694±1.236-fold upregulated in 20 tumor tissues versus adjacent nontumor tissues.

4. Discussion

Although some progress has been made in the study of HCC, the exact mechanisms of occurrence and development in HCC are not yet clear. In the current study, we constructed networks related to transcription regulatory modes in HCC and performed functional and KEGG pathway analysis for the key genes. The enrichment analysis results showed that key genes in the TF regulatory network were enriched in the p53 signaling pathway. In addition, we performed qRT-PCR and verification in the TCGA Dataset to confirm the results based on bioinformatics analysis.

FOS (also known as c-FOS) and FOSB were both protooncogenes, which belong to the activator protein 1 (AP1) family [27]. Many studies have reported that FOS was involved in proliferation, migration, and invasion of some malignancies [28, 29]. In some cases, expression of the FOS gene has also been associated with apoptotic cell death [30]. However, there still existed some contradictions about the role that c-FOS might play in the tumor progression. Some studies showed that overexpression of FOS might be associated with inhibition of tumor [31, 32]. Oliveira-Ferrer L et al. reported that c-FOS overexpression increased the apoptotic potential of ovarian cancer cells and inhibited tumor growth and metastasis, which could be achieved by changing the adhesion of human ovarian cancer cell [33]. A study by Guo J et al. showed that the expression of c-FOS in the tumor tissues of pancreatic cancer seemed to be lower than that in adjacent nontumor tissues [34]. However, some other research showed that FOS could contribute to carcinogenesis [35, 36]. Therefore, the above research work indicated that c-FOS is expressed differently in different histological types and is closely related to the proliferation, differentiation, invasion, and apoptosis of tumor cells, which provided a new therapeutic target for cancer by regulating the expression of c-FOS. EGR1 (early growth response 1) belongs to EGR...
family of transcription factors that includes four members: EGR1, EGR2, EGR3, and EGR4. It is a nuclear protein and functions as a transcriptional regulator, which is a component of p53 signaling [37, 38]. Abundant studies found that expression of EGR1 was associated with HCC metastasis and proliferation [39, 40]. And a number of studies suggested that EGR1 exhibits prominent tumor-suppressive activity by activating major tumor suppressor factors, including transforming growth factor-β1, p53, p73, fibronectin, and PTEN [40, 41]. In the present study, the mRNA expression of FOS and EGR1 was lower in HCC tissues than that in nontumor adjacent tissues based on bioinformatics analysis and qPCR verification. And the low expression of FOS and EGR1 was negatively associated with overall survival of HCC patients based on TCGA data, although this correlation was not statistically significant. The results above suggested that EGR1, FOS, and FOSB, three cancer-related TFs, could play an important role in the progression of HCC.

In the current study, we found that miR-181a-5p was upregulated in HCC based on miRNA microarray data and qRT-PCR verification. As a member of the miR-181 family, the level of miR-181a-5p was overexpressed in many cancers including breast cancers, multiple myeloma, pancreatic and gastric cancer, and hepatocellular carcinoma [42–45]. And
Table 7: Enrichment analysis of key genes.

(a) Top 10 enriched biological processes of key genes

| GO_Name                                    | GO_ID          | P value      | Count |
|--------------------------------------------|----------------|--------------|-------|
| response to chemical                       | GO:0042221     | 4.35E-16     | 29    |
| cellular response to chemical stimulus     | GO:0070887     | 8.93E-16     | 25    |
| response to oxygen-containing compound     | GO:3901700     | 4.92E-14     | 18    |
| response to drug                           | GO:0042493     | 7.49E-14     | 12    |
| response to stimulus                       | GO:0050896     | 2.07E-13     | 38    |
| response to organic substance              | GO:0010033     | 2.53E-13     | 23    |
| negative regulation of cellular process    | GO:0048523     | 6.20E-13     | 26    |
| regeneration                               | GO:0031099     | 1.64E-12     | 9     |
| animal organ development                    | GO:0048513     | 1.78E-12     | 22    |
| negative regulation of biological process  | GO:0048519     | 6.23E-12     | 26    |

(b) Top 10 enriched molecular functions of key genes

| GO_Name                                                                 | GO_ID          | P value      | Count |
|-------------------------------------------------------------------------|----------------|--------------|-------|
| protein binding                                                         | GO:0005515     | 4.10E-08     | 32    |
| oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor | GO:0033695 | 5.81E-06 | 2 |
| caffeine oxidase activity                                               | GO:0034875     | 5.81E-06     | 2     |
| cyclin-dependent protein kinase activity                                | GO:0097472     | 8.20E-06     | 3     |
| growth factor binding                                                   | GO:0019838     | 3.10E-05     | 4     |
| extracellular matrix binding                                            | GO:0050840     | 4.22E-05     | 3     |
| chemokine activity                                                      | GO:0008009     | 4.81E-05     | 3     |
| oxidoreductase activity, acting on CH or CH2 groups                     | GO:0016725     | 5.31E-05     | 2     |
| receptor binding                                                        | GO:0005102     | 5.38E-05     | 10    |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | GO:0016712 | 6.90E-05 | 3 |

(c) Top 10 enriched cell components of key genes

| GO_Name                                    | GO_ID          | P value      | Count |
|--------------------------------------------|----------------|--------------|-------|
| extracellular region part                  | GO:0044421     | 1.59E-09     | 20    |
| extracellular region                       | GO:005576      | 1.97E-09     | 22    |
| extracellular space                        | GO:0005615     | 2.94E-09     | 14    |
| membrane-bounded organelle                 | GO:0043227     | 1.77E-08     | 38    |
| cytoplasm                                 | GO:0005737     | 2.42E-08     | 36    |
| platelet alpha granule lumen               | GO:0031093     | 5.55E-07     | 4     |
| organelle                                 | GO:0043226     | 1.09E-06     | 38    |
| platelet alpha granule                     | GO:0003091     | 1.91E-06     | 4     |
| cytoplasmic part                          | GO:0044444     | 2.72E-06     | 30    |
| membrane-bounded vesicle                   | GO:0031988     | 3.14E-06     | 15    |

(d) Top 10 enriched KEGG pathway of key genes

| Pathway Name                              | Pathway ID     | P value      | Count |
|-------------------------------------------|----------------|--------------|-------|
| p53 signaling pathway                     | hsa04115       | 8.24E-09     | 7     |
| Cell cycle                                | hsa04110       | 1.31E-04     | 5     |
| Retinol metabolism                        | hsa00830       | 1.31E-04     | 4     |
| AMPK signaling pathway                     | hsa04152       | 1.36E-04     | 5     |
| Drug metabolism - cytochrome P450         | hsa00982       | 1.65E-04     | 4     |
| Metabolism of xenobiotics by cytochrome P450 | hsa00980   | 2.06E-04     | 4     |
| Progesterone-mediated oocyte maturation    | hsa04914       | 6.36E-04     | 4     |
| Oocyte meiosis                            | hsa04114       | 1.49E-03     | 4     |
| Steroid hormone biosynthesis              | hsa00140       | 1.65E-03     | 3     |
| FoxO signaling pathway                     | hsa04068       | 2.04E-03     | 4     |
Figure 7: Study of the clinical association of EGR1, FOS, FOSB, CCNB1, CCNB2, and CHEK1 with the clinicopathologic parameters of hepatocellular carcinoma. (a) Boxplots depicting RNA expression levels of key genes in HCC (n = 371) versus nonmalignant liver (n = 50) from TCGA. (b) Kaplan-Meier plots comparing the overall survival rates in HCC cases (n=365) with high expression or without low/medium expression. The data was recruited from UALCAN. P < 0.05 was considered statistically significant. (c) Correlation analysis of three TFs and three p53 markers. The data was recruited from Linkedomics (http://www.linkedomics.org).
Table 8: Primer sequences used for qRT-PCR amplification.

| Primer   | 5’ > 3’                                      |
|----------|----------------------------------------------|
| EGR1     | CACCTGACCCGCAGATCTTT                        |
|          | GAGTGGTTGGCTGGGAATTGAA                      |
| FOS      | GGGGCAAGGTTGAACAGTTA                       |
|          | AGTGGTGCTGTCTCCGCGTTG                      |
| FOSB     | GCGCCGGGAACCAAATAAAC                       |
|          | AACTGATCTGTCTCCCGCT                        |
| CCNB1    | AATAAGGGCAAGATCAACATGGC                     |
|          | TTGTCTAAAATGTCCCGAAGG                      |
| CCNB2    | CCGACGGTGTCAGTGATTT                       |
|          | TGTTGTTTGGTTGGGTTGA                        |
| CHEK1    | ATATGAAAGCTGCCGCTAGACT                     |
|          | TGACTATGTCTGGCTCTATTCTG                    |
| GAPDH    | GACAGTCAGCCGCATCTCTCT                     |
|          | ACCAAATCCGTTGACCTCGA                      |
| hsa-U6   | CTGCGTTCGCGACACACA                       |
|          | AACGCTTCCAGAAATTGGCCGT                     |
| hsa-miR-181a-5p | ACGCTGACCTATGAAATTGGACGACC         |

Figure 8: Validation of key genes and hsa-miR-181a-5p expression in 20 pairs of HCC and adjacent non-tumor tissues by qRT-PCR. Detection of EGR1, FOS, FOSB, CCNB1, CCNB2, and CHEK1 mRNA expression and hsa-miR-181a-5p expression in HCC versus adjacent non-tumor tissues was performed using qRT-PCR. Levels of EGR1, FOS, and FOSB mRNA were 3.938±0.551-, 3.508-fold upregulated. The relative expression of hsa-miR-181a-5p was 1.694±1.236-fold upregulated. *p<0.05, **p<0.01, and ***p<0.001.

5. Conclusion

Using multiple cohorts profile datasets and integrated bioinformatic analysis, we identified commonly 237 DEGs, and finally found EGR1, FOS, and FOSB, 3 cancer-related TFs, which were downregulated in HCC. In addition, we constructed the transcription factor-related regulatory networks.
based on EGRI, FOS, and FOSB and identified possible miR-181a-5p—FOS/EGRI—>p53 signaling pathway axis. It should be noted that this study examined the conclusion by qRT-PCR and bioinformatics analysis; further research needs to be done to explore more specific mechanisms. Notwithstanding its limitation, these findings significantly improved the understanding of underlying molecular mechanisms in HCC, and the key genes and pathways could be used as diagnostic and therapeutic targets and diagnostic biomarkers.

Data Availability

Expression profiles of GSE84402, GSE33006, GSE84005, GSE12941, and GSE64632 in the manuscript were downloaded from NCBI-GEO (https://www.ncbi.nlm.nih.gov/gds).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors were involved in the study and approved the final version of the manuscript.

Acknowledgments

The work was funded by the project of Hepatobiliary and Pancreatic Disease Translational Medicine Platform Construction (2017F009).

Supplementary Materials

Figure S1: KEGG mapping analysis diagram of 42 key genes most enriched pathway (p53 signaling pathway). Table S1: clinicopathological characteristics of 20 HCC patients. Table S2: 62 regulation modes formed by 42 differentially expressed mRNAs in the TF-gene regulatory network. All regulation information was derived from TRRUST version 2. Table S3: prediction results of differentially expressed miRNA targets in HCC by miRTarbase. (Supplementary Materials)

References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.

[2] S. P. Choo, W. L. Tan, B. K. P. Goh, W. M. Tai, and A. X. Zhu, “Comparison of hepatocellular carcinoma in Eastern versus Western populations,” Cancer, vol. 122, no. 22, pp. 3430–3446, 2016.

[3] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.

[4] H. Wang, X. Huo, X.-R. Yang et al., “STAT3-mediated upregulation of IncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4,” Molecular Cancer, vol. 16, no. 1, article no. 136, 2017.

[5] D. Sun, X. Wang, G. Sui, S. Chen, M. Yu, and P. Zhang, “Down-regulation of miR-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins,” International Journal of Oncology, 2018.

[6] O. V. Grinchuk, S. P. Yenamandra, R. Iyer et al., “Tumor-adja-cent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma,” Molecular Oncology, vol. 12, no. 1, pp. 89–113, 2018.

[7] Y. Zhang, J.-C. Huang, K.-T. Cai et al., “Long non-coding RNA HOTTIP promotes hepatocellular carcinoma tumorigenesis and development: A comprehensive investigation based on bioinformatics, qRT-PCR and meta-Analysis of 393 cases,” International Journal of Oncology, vol. 51, no. 6, pp. 1705–1721, 2017.

[8] F. Kong, T. Zhu, N. Li et al., “Bioinformatics analysis of the proteins interacting with LASP-1 and their association with HBV-related hepatocellular carcinoma,” Scientific Reports, vol. 7, no. 1, 2017.

[9] Y. Zhang, R. Kang, W. Liu et al., “Identification and analysis of P53-mediated competing endogenous RNA network in human hepatocellular carcinoma,” International Journal of Biological Sciences, vol. 13, no. 9, pp. 1213–1221, 2017.

[10] K. Liu, J. Lee, J. Y. Kim et al., “Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells,” Molecular Cell, vol. 68, no. 2, pp. 281–292.e5, 2017.

[11] M. Ye, Z. Fang, H. Gu et al., “Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1α under hypoxia condition,” Tumor Biology, vol. 39, no. 6, Article ID 1010428317705034, 2017.

[12] S. Hua, L. Lei, L. Deng et al., “MiR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1,” Oncogene, vol. 37, no. 12, pp. 1624–1636, 2018.

[13] Q. Zhang, G. Song, L. Yao et al., “miR-3928 is induced by HBx via NF-kB/EGRI and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3,” Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, 2018.

[14] The Gene Ontology Consortium, “Expansion of the Gene Ontology: function classification of proteins viewed globally in context,” Nucleic Acids Research, vol. 25, no. D1, pp. D331–D338, 2017.

[15] M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000.

[16] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, “KEGG: new perspectives on genomes, pathways, diseases and drugs,” Nucleic Acids Research, vol. 45, no. 1, pp. D353–D361, 2017.

[17] M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000.

[18] Y. Huang, H.-C. Chen, C.-W. Chiang, C.-T. Ye, S.-J. Chen, and C.-K. Chou, “Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells,” Nucleic Acids Research, vol. 40, no. 20, pp. 10478–10493, 2012.

[19] R. Satow, M. Shitashige, Y. Kanai et al., “Combined functional genome survey of therapeutic targets for hepatocellular carci-noma,” Clinical Cancer Research, vol. 16, no. 9, pp. 2518–2528, 2010.
[20] H. Peng, M. Ishida, L. Li et al., "Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma," Oncotarget, vol. 6, no. 8, pp. 5666–5677, 2015.

[21] H. Su, J. Yang, T. Xu et al., "MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity," Cancer Research, vol. 69, no. 3, pp. 1135–1142, 2009.

[22] F. Zhao, Z. Xuan, L. Liu, and M. Q. Zhang, "TRED: a transcriptional regulatory element database and a platform for in silico gene regulation studies," Nucleic Acids Research, vol. 33, pp. D103–D107, 2005.

[23] H. Han, J.-W. Cho, S. Lee et al., "TRRUST v2: An expanded reference database of human and mouse transcriptional regulatory interactions," Nucleic Acids Research, vol. 46, no. 1, pp. D380–D386, 2018.

[24] C.-H. Chou, S. Shrestha, C.-D. Yang et al., "MiRTarBase update 2018: A resource for experimentally validated microRNA-target interactions," Nucleic Acids Research, vol. 46, no. 1, pp. D296–D302, 2018.

[25] D. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanyan et al., "UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses," Neoplasia (United States), vol. 19, no. 8, pp. 649–658, 2017.

[26] S. V. Vasaikar, P. Straub, J. Wang, and B. Zhang, "LinkEdomics: Analyzing multi-omics data within and across 32 cancer types," Nucleic Acids Research, vol. 46, no. 1, pp. D956–D963, 2018.

[27] B. L. Caputto, A. M. Cardozo Gizzi, and G. A. Gil, "C-Fos: An AP-1 transcription factor with an additional cytoplasmic, non-genomic lipid synthesis activation capacity," Biochimica et Biophysica Acta (BBA) - Molecular and Cellular Biology of Lipids, vol. 1841, no. 9, pp. 1241–1246, 2014.

[28] H. Li, J. Li, S. Jia et al., "miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer," Oncotarget, vol. 6, no. 3, pp. 31958–31984, 2015.

[29] K. Milde-Langosch, "The Fos family of transcription factors and their role in tumourigenesis," European Journal of Cancer, vol. 41, no. 16, pp. 2449–2461, 2005.

[30] L. Min, Y. Ji, L. Bakiri et al., "Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin," Nature Cell Biology, vol. 14, no. 11, pp. 1203–1211, 2012.

[31] T. Zhang, X. Fan, L. Song et al., "c-Fos is involved in inhibition of human bladder carcinoma T24 cells by Brazilian, IUBMB Life, vol. 67, no. 3, pp. 175–181, 2015.

[32] S. P. Jin, J. H. Kim, M. A. Kim et al., "Prognostic significance of loss of c-fos protein in gastric carcinoma," Pathology & Oncology Research, vol. 13, no. 4, pp. 284–289, 2007.

[33] L. Oliveira-Ferrao, K. Rößler, V. Haustein et al., "C-FOS suppresses ovarian cancer progression by changing adhesion," British Journal of Cancer, vol. 110, no. 3, pp. 753–763, 2014.

[34] J. Guo, J. Li, Y. Zhao et al., "Expression of c-fos was associated with clinicopathologic characteristics and prognosis in pancreatic cancer," PLoS ONE, vol. 10, no. 3, p. e0120332, 2015.

[35] L. Bakiri, R. Hamacher, O. Graña et al., "Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation," The Journal of Experimental Medicine, vol. 214, no. 5, pp. 1387–1409, 2017.

[36] N. Muhammad, S. Bhattacharya, R. Steele, N. Phillips, and R. B. Ray, "Involvement of C-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma," Clinical Cancer Research, vol. 23, no. 12, pp. 3120–3128, 2017.

[37] V. Baron, E. D. Adamson, A. Calogero, G. Ragona, and D. Mercola, "The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ/PTEN, p53 and fibronectin," Cancer Gene Therapy, vol. 13, no. 2, pp. 115–124, 2006.

[38] A. Krones-Herzig, S. Mittal, K. Yule et al., "Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53," Cancer Research, vol. 65, no. 12, pp. 5133–5143, 2005.

[39] C. Z. Zhang, S. Chen, C. Wang et al., "CBX8 exhibits oncogenic activity via AKT/β-catenin activation in hepatocellular carcinoma," Cancer Research, vol. 78, no. 1, pp. 51–63, 2018.

[40] L. Wang, H. Sun, X. Wang et al., "EGR1 mediates miR-203a suppression the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway," Oncotarget, vol. 7, no. 29, pp. 45302–45316, 2016.

[41] S. Chang, B. Chen, X. Wang, K. Wu, and Y. Sun, "Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression," BMC Cancer, vol. 17, no. 1, article no. 248, 2017.

[42] B. Yan, H. Li, X. Yang et al., "Unraveling regulatory programs for NF-kappaB, p53 and MicroRNAs in head and neck squamous cell carcinoma," PLoS ONE, vol. 8, no. 9, p. e73656, 2013.

[43] J.-C. Neel and J.-J. Lebrun, "Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells," Cellular Signalling, vol. 25, no. 7, pp. 1556–1566, 2013.

[44] J. Liu, D. Xu, Q. Wang, D. Zheng, X. Jiang, and L. Xu, "LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and MAP2K4," Digestive Diseases and Sciences, vol. 59, no. 7, pp. 1452–1460, 2014.

[45] C. Pop-Bica, S. Pintea, R. Cojocneanu-Petric et al., "MiR-181 family-specific behavior in different cancers: a meta-analysis view," Cancer and Metastasis Reviews, vol. 37, no. 1, pp. 17–32, 2018.

[46] J. Brockhausen, S. S. Tay, and C. A. Grzelak, "miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer," Liver International, vol. 35, no. 1, pp. 240–253, 2014.

[47] J. Yang, Y. He, N. Zhai, S. Ding, J. Li, and Z. Peng, "MicroRNA-181a induces autophagy by targeting Atg5 in hepatocellular carcinoma," Frontiers in Bioscience, vol. 23, no. 1, pp. 388–396, 2018.

[48] C. Zou, J. Chen, K. Chen et al., "Functional analysis of miR-181a and Fas involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis," Experimental Cell Research, vol. 331, no. 2, pp. 352–361, 2015.

[49] S. Y. Wu, R. Rupaimoole, F. Shen et al., "A miR-192-EGFR-HOXB9 regulatory network controls the angiogenic switch in cancer," Nature Communications, vol. 7, 2016.

[50] J. Z. Zhu, K. Yao, J. Guo et al., "miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1–STAT1/c-Fos pathway," Journal of Cellular and Molecular Medicine, vol. 21, no. 11, pp. 2884–2895, 2017.

[51] C. Wu, Y. Gong, J. Yuan et al., "microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos," Journal of Lipid Research, vol. 53, no. 11, pp. 2355–2363, 2012.

[52] P. Xu, M.-P. Guan, J.-G. Bi, D. Wang, Z.-J. Zheng, and Y.-M. Xue, "High glucose down-regulates microRNA-181a-5p to increase pro-fibrotic gene expression by targeting early growth response
factor 1 in HK-2 cells,” *Cellular Signalling*, vol. 31, pp. 96–104, 2017.

[53] J. Krstic, M. Galhuber, T. Schulz, M. Schupp, and A. Prokesch, “p53 as a dichotomous regulator of liver disease: the dose makes the medicine,” *International Journal of Molecular Sciences*, vol. 19, no. 3, p. 921, 2018.

[54] Y. Kong, L. Zhang, Y. Huang et al., “Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway,” *Cancer Letters*, vol. 407, pp. 76–83, 2018.

[55] X. Li, J. Yu, M. V. Brock et al., “Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU,” *Oncotarget*, vol. 6, no. 13, pp. 11547–11560, 2015.

[56] H.-C. Kirch, S. Flaswinkel, H. Rumpf, D. Brockmann, and H. Esche, “Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kB and Myc/Max,” *Oncogene*, vol. 18, no. 17, pp. 2728–2738, 1999.

[57] J. Guinea-Viniegra, R. Zenz, H. Scheuch et al., “Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17,” *The Journal of Clinical Investigation*, vol. 122, no. 8, pp. 2898–2910, 2012.

[58] Z. Wang, M. Fan, D. Candas et al., “Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression,” *Developmental Cell*, vol. 29, no. 2, pp. 217–232, 2014.

[59] H. Nam and J. M. van Deursen, “Cyclin B2 and p53 control proper timing of centrosome separation,” *Nature Cell Biology*, vol. 16, no. 6, pp. 538–549, 2014.

[60] H. Chiu, W. Huang, T. Liao et al., “Mechanistic insights into avian reovirus p17-modulated suppression of cell-cycle CDK/cyclin complexes and enhancement of p53 and cyclin H interaction,” *The Journal of Biological Chemistry*, Article ID jbc.RA118.002341, 2018.

[61] J. J. Geenen and J. H. M. Schellens, “Molecular pathways: Targeting the protein kinase Wee1 in cancer,” *Clinical Cancer Research*, vol. 23, no. 16, pp. 4540–4544, 2017.

[62] Y. Zhang and T. Hunter, “Roles of Chk1 in cell biology and cancer therapy,” *International Journal of Cancer*, vol. 134, no. 5, pp. 1013–1023, 2014.

[63] T. Fishler, Y.-Y. Li, R.-H. Wang et al., “Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53,” *Oncogene*, vol. 29, no. 28, pp. 4007–4017, 2010.

[64] H. Jin, G. Xu, Q. Zhang, Q. Pang, and M. Fang, “Synaptotagmin-7 is overexpressed in hepatocellular carcinoma and regulates hepatocellular carcinoma cell proliferation via Chk1–p53 signaling,” *Oncotargets and Therapy*, vol. 10, pp. 4283–4293, 2017.

[65] Y.-L. Nan, Y.-L. Hu, Z.-K. Liu et al., “Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma,” *World Journal of Gastroenterology*, vol. 22, no. 24, pp. 5558–5567, 2016.

[66] A. Malki, R. Y. Elbayaa, O. Ali, A. Sultan, and A. M. Youssef, “Novel quinuclidinone derivatives induced apoptosis in human breast cancer via targeting p53,” *Bioorganic Chemistry*, vol. 72, pp. 57–63, 2017.

[67] S. Di Agostino, G. Sorrentino, E. Ingallina et al., “YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins,” *EMBO Reports*, vol. 17, no. 2, pp. 188–201, 2016.

[68] L. Zheng, Y. Zhu, L. Lei, W. Sun, G. Cheng, and S. Yang, “Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis,” *Oncology Letters*, vol. 15, no. 1, pp. 568–574, 2017.